From New Year's Day in 2022, patients with moderate and severe allergic asthma treated with omazumab can apply for medical insurance reimbursement. Only when the materials meet the requirements and pass the examination can you enjoy more than 50% medical insurance reimbursement. Children with atopic dermatitis over 6 years old can also be reimbursed with duprizumab.
The indications of omazumab in the treatment of chronic spontaneous urticaria have successfully entered the medical insurance catalogue, which will effectively improve the accessibility of drugs and reduce the treatment burden of patients.